Should I buy or sell NuCana stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NuCana in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NCNA shares. View NCNA analyst ratings or view top-rated stocks .

What is NuCana's stock price target for 2024?

2 brokers have issued 1-year price objectives for NuCana's stock. Their NCNA share price targets range from $100.00 to $150.00. On average, they predict the company's share price to reach $125.00 in the next twelve months. This suggests a possible upside of 3,324.7% from the stock's current price. View analysts price targets for NCNA or view top-rated stocks among Wall Street analysts .

How have NCNA shares performed in 2024?

NuCana's stock was trading at $7.3950 on January 1st, 2024. Since then, NCNA stock has decreased by 50.6% and is now trading at $3.65. View the best growth stocks for 2024 here .

Are investors shorting NuCana?

NuCana saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 164,900 shares, a drop of 93.4% from the March 15th total of 2,480,000 shares. Based on an average daily volume of 1,580,000 shares, the short-interest ratio is currently 0.1 days. Approximately 0.4% of the company's shares are sold short. View NuCana's Short Interest .

When is NuCana's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 15th 2024. View our NCNA earnings forecast .

How were NuCana's earnings last quarter?

NuCana plc (NASDAQ:NCNA) issued its earnings results on Wednesday, March, 20th. The company reported ($4.25) EPS for the quarter, missing analysts' consensus estimates of ($3.25) by $1.00.

When did NuCana's stock split?

Shares of NuCana reverse split before market open on Tuesday, April 16th 2024. The 1-25 reverse split was announced on Tuesday, April 16th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, April 16th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What other stocks do shareholders of NuCana own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NuCana investors own include Wirecard (WDI) , VBI Vaccines (VBIV) , Sorrento Therapeutics (SRNE) , Ovid Therapeutics (OVID) , SCYNEXIS (SCYX) , Aldeyra Therapeutics (ALDX) , Allena Pharmaceuticals (ALNA) , Pfizer (PFE) , Rigel Pharmaceuticals (RIGL) and Tetraphase Pharmaceuticals (TTPH) .

NuCana (NCNA) raised $100 million in an initial public offering (IPO) on Thursday, September 28th 2017. The company issued 6,700,000 shares at $14.00-$16.00 per share. Citigroup, Jefferies and Cowen acted as the underwriters for the IPO and William Blair was co-manager.

How do I buy shares of NuCana?

Shares of NCNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:NCNA

NuCana (NCNA) Stock Price, News & Analysis

→ Will this $2 AI stock double overnight? (From Behind the Markets) (Ad)

Free NCNA Stock Alerts

$3.78

-0.01 (-0.26%)

(As of 03:40 PM ET)

Compare

Today's Range: $3.40
▼
$3.82
50-Day Range: $3.79
▼
$10.50
52-Week Range: $3.40
▼
$23.75

Volume: 32,574 shs
Average Volume: 59,676 shs
Market Capitalization: $7.90 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $125.00

Get NuCana alerts:

NuCana MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 3,324.7% Upside
$125.00 Price Target
Short Interest: Healthy
0.35% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.94
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($12.06) to ($11.81) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.66 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
NuCana has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
NuCana has only been the subject of 1 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.35% of the float of NuCana has been sold short.
Short Interest Ratio / Days to Cover
NuCana has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in NuCana has recently decreased by 93.35%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
NuCana does not currently pay a dividend.
Dividend Growth
NuCana does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for NCNA.

3.3

News and Social Media Coverage

News Sentiment
NuCana has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for NuCana this week, compared to 1 article on an average week.
Search Interest
Only 1 people have searched for NCNA on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days.
MarketBeat Follows
7 people have added NuCana to their MarketBeat watchlist in the last 30 days. This is an increase of 133% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, NuCana insiders have not sold or bought any company stock.
Percentage Held by Insiders
31.20% of the stock of NuCana is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
44.00% of the stock of NuCana is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for NuCana are expected to grow in the coming year, from ($12.06) to ($11.81) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of NuCana is -0.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of NuCana is -0.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
NuCana has a P/B Ratio of 0.41. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Behind the Markets

The #1 Opportunity of the decade?

It's no wonder the Department of Defense is heavily invested in this technology. And why The Pentagon is pouring $20 billion into it.

Click here to learn more >>>

About NuCana Stock (NASDAQ:NCNA)

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. The company applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing medicines, ProTides, to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil, which is in a Phase 1b/2 study in patients with metastatic colorectal cancer. The company also initiated a randomized Phase 2 study of NUC-3373, in combination with other agents, for the second-line treatment of patients with advanced colorectal cancer; and initiated a Phase 1b/2 modular study of NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid tumors and in combination with docetaxel for patients with lung cancer. Its pipeline also comprises NUC-7738, a transformation of 3'-deoxyadenosine that is in the Phase 2 part of a Phase 1/2 study in patients with advanced solid tumors which is evaluating NUC-7738 as a monotherapy and in combination with pembrolizumab. It has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.

NCNA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

NCNA Stock News Headlines

April 18, 2024 | finance.yahoo.com

NuCana plc (NCNA)

April 16, 2024 | finance.yahoo.com

NuCana Announces Completion of ADS Ratio Change

April 19, 2024 | Behind the Markets (Ad)

Will this $2 AI stock double overnight?

It's a tiny AI company fighting for a big piece of a $20 Billion Pentagon contract. What's more, this groundbreaking firm is trading for less than $2 a share!

April 9, 2024 | globenewswire.com

NuCana Presents Data at the AACR 2024 Annual Meeting Highlighting the Ability of NUC-7738 to Profoundly Alter Tumor Biology in a Paired Biopsy Clinical Study

April 5, 2024 | benzinga.com

NuCana Stock (NASDAQ:NCNA), Quotes and News Summary

March 28, 2024 | msn.com

Why NuCana (NCNA) Shares Are Trading Lower

March 27, 2024 | finanznachrichten.de

NuCana plc: NuCana Announces Plan to Implement ADS Ratio Change

March 27, 2024 | marketwatch.com

NuCana American Depositary Shares Fall on News of Planned Ratio Change

April 19, 2024 | Behind the Markets (Ad)

Will this $2 AI stock double overnight?

It's a tiny AI company fighting for a big piece of a $20 Billion Pentagon contract. What's more, this groundbreaking firm is trading for less than $2 a share!

March 27, 2024 | globenewswire.com

NuCana Announces Plan to Implement ADS Ratio Change

March 25, 2024 | markets.businessinsider.com

Nucana (NCNA) Receives a Hold from TD Cowen

March 20, 2024 | benzinga.com

NuCana: Q4 Earnings Insights

March 20, 2024 | globenewswire.com

NuCana Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update

March 14, 2024 | finance.yahoo.com

NuCana (NASDAQ:NCNA) Will Have To Spend Its Cash Wisely

March 13, 2024 | msn.com

Why NuCana Stock Is Up Today

March 13, 2024 | msn.com

Why Is Surgepays (SURG) Stock Down 27% Today?

March 13, 2024 | investorplace.com

Why Is NuCana (NCNA) Stock Up 102% Today?

February 27, 2024 | finanznachrichten.de

NuCana plc: NuCana to Present at TD Cowen's 44th Annual Health Care Conference

February 27, 2024 | finance.yahoo.com

NuCana to Present at TD Cowen’s 44th Annual Health Care Conference

February 27, 2024 | globenewswire.com

NuCana to Present at TD Cowen's 44th Annual Health Care Conference

February 26, 2024 | msn.com

European Equities Traded in the US as American Depositary Receipts Open Week Flat in Monday Trading

February 23, 2024 | msn.com

European Equities Traded in the US as American Depositary Receipts Rise Friday, Set to End Week Up 1.5%

February 6, 2024 | finanznachrichten.de

NuCana plc: NuCana to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

February 6, 2024 | finance.yahoo.com

NuCana to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

January 31, 2024 | msn.com

European Equities Traded in the US as American Depositary Receipts Move Modestly Higher in Wednesday Trading

January 3, 2024 | seekingalpha.com

NuCana: Potential Turnaround In 2024 But Risky

December 29, 2023 | msn.com

European Equities Traded in the US as American Depositary Receipts Edge Higher Friday

See More Headlines

Receive NCNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NuCana and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/20/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/15/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:NCNA
CUSIP: N/A
CIK: 1709626
Web: www.nucana.com
Phone: 441313571111
Fax: N/A
Employees: 28
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $125.00
High Stock Price Target: $150.00
Low Stock Price Target: $100.00
Potential Upside/Downside: +3,278.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($16.00)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-34,370,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -115.42%
Return on Assets: -72.84%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.97
Quick Ratio: 1.97

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $8.85 per share
Price / Book: 0.42

Miscellaneous

Outstanding Shares: 2,090,000
Free Float: 1,439,000
Market Cap: $7.73 million
Optionable: Not Optionable
Beta: 0.92

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Mr. Hugh Stephen Griffith (Age 56)
Founder, CEO & Executive Director
Comp: $1.23M
Mr. Donald Munoz (Age 55)
Chief Financial Officer

Key Competitors

View All Competitors

Institutional Ownership

Citadel Advisors LLC
Bought 146,083 shares on 2/15/2024
Ownership: 0.279%

View All Institutional Transactions

NCNA Stock Analysis - Frequently Asked Questions

Should I buy or sell NuCana stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NuCana in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NCNA shares.
View NCNA analyst ratings or view top-rated stocks.
What is NuCana's stock price target for 2024?: 2 brokers have issued 1-year price objectives for NuCana's stock. Their NCNA share price targets range from $100.00 to $150.00. On average, they predict the company's share price to reach $125.00 in the next twelve months. This suggests a possible upside of 3,324.7% from the stock's current price.
View analysts price targets for NCNA or view top-rated stocks among Wall Street analysts.
How have NCNA shares performed in 2024?: NuCana's stock was trading at $7.3950 on January 1st, 2024. Since then, NCNA stock has decreased by 50.6% and is now trading at $3.65.
View the best growth stocks for 2024 here.
Are investors shorting NuCana?: NuCana saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 164,900 shares, a drop of 93.4% from the March 15th total of 2,480,000 shares. Based on an average daily volume of 1,580,000 shares, the short-interest ratio is currently 0.1 days. Approximately 0.4% of the company's shares are sold short.
View NuCana's Short Interest.
When is NuCana's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 15th 2024.
View our NCNA earnings forecast.
How were NuCana's earnings last quarter?: NuCana plc (NASDAQ:NCNA) issued its earnings results on Wednesday, March, 20th. The company reported ($4.25) EPS for the quarter, missing analysts' consensus estimates of ($3.25) by $1.00.

When did NuCana's stock split?: Shares of NuCana reverse split before market open on Tuesday, April 16th 2024. The 1-25 reverse split was announced on Tuesday, April 16th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, April 16th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.
What other stocks do shareholders of NuCana own?: Based on aggregate information from My MarketBeat watchlists, some companies that other NuCana investors own include Wirecard (WDI), VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Ovid Therapeutics (OVID), SCYNEXIS (SCYX), Aldeyra Therapeutics (ALDX), Allena Pharmaceuticals (ALNA), Pfizer (PFE), Rigel Pharmaceuticals (RIGL) and Tetraphase Pharmaceuticals (TTPH).
When did NuCana IPO?: NuCana (NCNA) raised $100 million in an initial public offering (IPO) on Thursday, September 28th 2017. The company issued 6,700,000 shares at $14.00-$16.00 per share. Citigroup, Jefferies and Cowen acted as the underwriters for the IPO and William Blair was co-manager.
How do I buy shares of NuCana?: Shares of NCNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NCNA) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial